Generic drug

Oral Biologics & Biosimilars Global Market Report 2022: Rising Prevalence of Chronic Diseases Such as Arthritis, Asthma, and Cancer Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 5, 2022

The "Oral Biologics & Biosimilars Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oral Biologics & Biosimilars Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to propel the growth of the oral biologics and biosimilar market.
  • Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases, and biologics are increasingly used to treat these chronic diseases.
  • Therefore, the rise in the prevalence of chronic diseases is driving the growth of the biologics and biosimilar market.

Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Sealed Air Securities Litigation

Retrieved on: 
Wednesday, October 5, 2022

78u-4(a)(4) should be approved; and (5) whether the Judgment, in the form attached to the settlement agreement, should be entered.

Key Points: 
  • 78u-4(a)(4) should be approved; and (5) whether the Judgment, in the form attached to the settlement agreement, should be entered.
  • Please note that the date, time and location of the settlement hearing are subject to change without further notice.
  • IF YOU PURCHASED OR ACQUIRED ANY OF THE COMMON STOCK OF SEALED AIR DURING THE PERIOD FROM NOVEMBER 17, 2014 TO JUNE 20, 2019, INCLUSIVE, YOUR RIGHTS WILL BE AFFECTED BY THE SETTLEMENT OF THIS LITIGATION.
  • Unless the deadline is extended, your failure to submit your Proof of Claim by the above deadline will preclude you from receiving any payment from the Settlement.

District Court Rejects Asetek Patent Claims And Determines CoolIT Systems Non-Infringing

Retrieved on: 
Wednesday, October 5, 2022

CALGARY, Alberta, Oct. 5, 2022 /PRNewswire-PRWeb/ -- CoolIT Systems (CoolIT), the global leader in scalable liquid cooling technology for desktop and data centers, announced that on September 11, 2022 the United States District Court for the Northern District of California issued an Order that granted summary judgment of non-infringement for all of CoolIT's past and current products in regard to Asetek's U.S. Patent Number 8,240,362 (the '362 patent). The court also found that CoolIT's most recent pump design does not infringe either.

Key Points: 
  • CoolIT Systems and Asetek settle all outstanding litigation following Court Order that granted summary judgment of non-infringement for all of CoolIT Systems past and current products in regard to Asetek patent.
  • Following this summary judgment, CoolIT and Asetek settled all outstanding litigation between them, and CoolIT expects that the parties will soon submit a joint stipulation dismissing CoolIT's and Asetek's claims with prejudice.
  • On January 23, 2019, Asetek sued CoolIT for patent infringement regarding the aforementioned '362 patent and four additional U.S. patents, 8,245,764; 9,733,681; 10,078,354; and 10,078,355.
  • For more information about CoolIT Systems and its technology visit https://www.coolitsystems.com/ and follow @CoolIT Systems on LinkedIn.

Fragmented BCMO Market Pressured by Economic and Pharmaceutical Industry Factors

Retrieved on: 
Tuesday, October 4, 2022

ARLINGTON, Va., Oct. 4, 2022 /PRNewswire-PRWeb/ -- The global biopharmaceutical contract manufacturing organization (BCMO) industry is highly fragmented, with 40 BCMOs/CDMOs accounting for roughly one quarter of the industry's revenues and the remainder comprised of a large number of smaller players. Based upon 2021 figures, Catalent led the overall market with estimated BCMO sales of $2.2 billion It was followed closely by Cytiva with $2.0 billion While these market leaders are active in most of the geographic market segments, smaller players tend to focus on a few regions, particularly the U.S. and/or Western Europe. Besides market leaders, companies of interest include Dr. Reddy's as well as WuXi AppTec, Pfizer CentreOne, Baxter. This is according to Biopharmaceutical Contract Manufacturing Organization (BCMO) Market, 2022, Kalorama's latest report on the sector.

Key Points: 
  • Besides market leaders, companies of interest include Dr. Reddy's as well as WuXi AppTec, Pfizer CentreOne, Baxter.
  • This is according to Biopharmaceutical Contract Manufacturing Organization (BCMO) Market, 2022 , Kalorama's latest report on the sector.
  • Additionally, ongoing economic challenges will further pressure the industry, making drug maker financial performance even more important and tightening access to capital for smaller players.
  • While all of these factors are important, the impact of the economic pressures cannot be overstated since many drug makers are publicly traded and financial pressures directly impact their budgets.

Medical Composites Market to Exceed US$ 2.4 Billion by 2031 Amid Burgeoning Demand for Cosmetic Surgeries & Aesthetic Procedures

Retrieved on: 
Tuesday, October 4, 2022

NEW YORK, Oct. 4, 2022 /PRNewswire/ -- The global medical composites market is anticipated to grow at a CAGR of 9% during 2021-2031 and reach US$ 2.4 Billion by 2031. Growing use of medical composites in body implants, prosthetics, and other surgeries is likely to drive the market over the forecast period. Further, owing to their ability to generate low radiation, medical composites are being widely used in x-ray machines, which is likely to drive the market.

Key Points: 
  • NEW YORK, Oct. 4, 2022 /PRNewswire/ --The global medical composites market is anticipated to grow at a CAGR of 9% during 2021-2031 and reach US$ 2.4 Billion by 2031 .
  • Growing use of medical composites in body implants, prosthetics, and other surgeries is likely to drive the market over the forecast period.
  • Further, owing to their ability to generate low radiation, medical composites are being widely used in x-ray machines, which is likely to drive the market.
  • By fiber, demand for carbon fiber medical composites is projected to exhibit 8.4% CAGR from 2021 to 2031.

Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial

Retrieved on: 
Tuesday, October 4, 2022

At the time of topline analysis, the safety of TALZENNA plus XTANDI were generally consistent with the known safety profile of each medicine.

Key Points: 
  • At the time of topline analysis, the safety of TALZENNA plus XTANDI were generally consistent with the known safety profile of each medicine.
  • Detailed results from TALAPRO-2 will be submitted for presentation at a near-term medical congress.
  • In addition to the TALAPRO-2 trial, the combination of TALZENNA plus XTANDI is being investigated in the TALAPRO-3 trial ( NCT04821622 ), a global, randomized, double-blind, placebo-controlled Phase 3 study in men with HRR-deficient mCSPC.
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United States

Retrieved on: 
Monday, October 3, 2022

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced the commercial launch of ALYMSYS (bevacizumab-maly), a biosimilar referencing Avastin.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced the commercial launch of ALYMSYS (bevacizumab-maly), a biosimilar referencing Avastin.
  • The launch of ALYMSYS provides additional access and choice to affordable oncology therapeutics for providers and patients.
  • Amneal has officially entered the U.S. biosimilar market.
  • We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States.

FDA Awards $1.3 Million Grant to Biologics & Biosimilars Collective Intelligence Consortium

Retrieved on: 
Monday, October 3, 2022

ALEXANDRIA, Va., Oct. 3, 2022 /PRNewswire/ -- The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) announcedtodaythatithasreceivedamajorgrantfromtheFood& Drug Administration (FDA) in support of biosimilars research.

Key Points: 
  • ALEXANDRIA, Va., Oct. 3, 2022 /PRNewswire/ -- The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) announcedtodaythatithasreceivedamajorgrantfromtheFood& Drug Administration (FDA) in support of biosimilars research.
  • The award provides $1.3 million over two years for a new BBCIC study focused on increasing the efficiency of biosimilar drug development and review.
  • Thestudyentitled"ImprovingtheEfficiencyofRegulatoryDecisions forBiosimilarsand Interchangeable Biosimilars by Leveraging Real-World Data to Produce Real-World Evidence"reflects BBCIC's longstanding commitment to evaluating the safety and effectiveness of biologics, including biosimilars, through the generation of reliable, real- world data (RWD) and evidence (RWE).
  • "The challenges in using real-world data and the relevance of real-world evidence for regulatorydecision-makingaboutbiosimilarsis amajorobstacle intheindustry,"saidCate Lockhart, Executive Director of the BBCIC.

Dr. Brian Gray named Chief Dental Officer at Candid

Retrieved on: 
Monday, October 3, 2022

NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Few dental professionals can claim the level of achievement of Brian Gray, DDS.

Key Points: 
  • NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Few dental professionals can claim the level of achievement of Brian Gray, DDS.
  • Now, one of the most accomplished dental professionals is joining Candid as Chief Dental Officer as they seek to revolutionize the clear aligner industry.
  • As Chief Dental Officer, Dr. Gray will engage our CandidPro partners while also guiding the evolution of our clinical features," says CEO Nick Greenfield.
  • Since 2017, Candid has brought high-quality orthodontic care and patient support to dental practices and dental service organizations across the United States.

Global Pharmaceutical Excipients Market Report 2022: Expanding Pharmaceutical Sector, and Increased R&D Activity Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, October 3, 2022

The "Pharmaceutical Excipients Market Analysis by Product, by Functionality, by Formulations, and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmaceutical Excipients Market Analysis by Product, by Functionality, by Formulations, and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The pharmaceutical excipients market size is estimated to be USD 7.9 billion in 2021 and is expected to witness a CAGR of 8.6% during the forecast period 2022-2029.
  • The expanding pharmaceutical sector, and increased R&D activity in this area are the factors contributing to the market growth.
  • Segmentation: Pharmaceutical Excipients Market Report 2021-2029Product (Revenue, USD Billion)